ARTICLE | Clinical News

Inflazyme preclinical data

April 17, 1995 7:00 AM UTC

The Vancouver company announced that the anti-asthma compound prevented allergic asthmatic reactions in sheep, particularly the late-phase response, which was entirely blocked. The drug also reduced bronchial hyper-responsiveness by 50 percent.

The preliminary results were obtained in eight animals, and further tests are in progress. ...